Impact of donor and recipient race on survival after hepatitis c-related liver transplantation

Transplantation

Volumn 93, Issue 4, 2012, Pages 444-449

  Layden, Jennifer E ^a   Cotler, Scott J ^a   Grim, Shellee A ^a   Fischer, Michael J ^a,b,c   Lucey, Michael R ^c,d   Clark, Nina M ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Hepatitis C virus (HCV); Liver transplantation; Race; Survival

Indexed keywords

ADULT; ARTICLE; CAUCASIAN; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE ASSOCIATION; DONOR SELECTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HIGH RISK PATIENT; HISPANIC; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; NEGRO; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RACE DIFFERENCE; RECURRENT INFECTION; RISK ASSESSMENT; SURGICAL MORTALITY; SURVIVAL PREDICTION; SURVIVAL RATE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HISPANIC AMERICANS; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TISSUE DONORS; TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84857064319     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182406a94     Document Type: Article

References (35)

1. Charlton M. Hepatitis C infection in liver transplantation. Am J Transplant 2001; 1: 197.
2. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009; 9: 1707.
3. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 88.
4. Velidedeoglu E, Mange K, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV+ recipients. Transplantation 2004; 77: 1834.
5. Rowe IA, Webb K, Gunson BK, et al. The impact of disease recurrence on graft survival following liver transplantation: A single centre experience. Transpl Int 2008; 21: 459.
6. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: A 10-year follow-up. Transplantation 2004; 77: 226.
7. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 2003; 9: S58.
8. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8(10 suppl 1): S14.
9. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673.
10. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815.
11. ShuhartMC,BronnerMP,GretchDR,et al. Histologicalandclinicaloutcome after liver transplantation for hepatitis C. Hepatology 1997; 26: 1646.
12. Yilmaz N, Shiffman ML, Stravitz RT, et al. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl 2007; 13: 975.
13. Gallegos-Orozco JF, Yosephy A, Noble B, et al. Natural history of postliver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl 2009; 15: 1872.
14. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
15. Ananthakrishnan AN, Saeian K. Racial differences in liver transplantation outcomes in the MELD era. Am J Gastroenterol 2008; 103: 901.
16. Neff GW, Kemmer N, Kaiser T, et al. Outcomes in adult and pediatric liver transplantation among various ethnic groups. Transplant Proc 2007; 39: 3204.
17. Nair S, Eustace J, Thuluvath PJ. Effect of race on outcome of orthotopic liver transplantation: A cohort study. Lancet 2002; 359: 287.
18. Yoo HY, Thuluvath PJ. Outcome of liver transplantation in adult recipients: Influence of neighborhood income, education, and insurance. Liver Transpl 2004; 10: 235.
19. Thuluvath PJ, Yoo HY, Thompson RE. A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics. Liver Transpl 2003; 9: 527.
20. Pang PS, Kamal A, Glenn J. The effect of donor race on the survival of Black Americans undergoing liver transplantation for chronic hepatitis C. Liver Transl 2009; 15: 1126.
21. Asrani SK, Lim YS, Therneau TM, et al. Donor race does not predict graft failure after liver transplantation. Gastroenterology 2010; 138: 2341.
22. Feng S, Goodrich NP, Bragg-Gresham J, et al. Characteristics associated with liver graft failure: The concept of a donor risk index. Am J Transplant 2006; 6: 783.
23. Rustgi VK, Marino G, Halpern MT, et al. Role of gender and race mismatch and graft failure in patients undergoing liver transplantation. Liver Transpl 2002; 8: 514.
24. Sterling RK, Stravitz RT, Luketic VT, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2: 469.
25. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: Its natural history and histological progression. Am J Gastroenterol 2002; 97: 700.
26. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556.
27. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787.
28. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 470.
29. Layden-Almer JE, Ribeiro RM, Wiley T, et al. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 3: 1343.
30. Muir AJ, Bornstein JD, Killenberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265.
31. Mathur AK, Sonnenday CJ, Merion RM. Race and ethnicity in access to and outcomes of liver transplantation: a critical review. Amer J Transplant. 2009; 9: 2662.
32. Haydon GH, Hiltunen Y, Lucey MR, et al. Self-organizing maps can determine outcome and match recipients and donors at orthotopic liver transplantation Transplantation 2005; 79: 213.
33. Schaubel DE, Sima CS, Goodrich NP, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8: 419.
34. Coombes JM, Trotter JF. Development of the allocation system for deceased donor liver transplantation. Clin Med Res 2005; 3: 87.
35. Department of Health and Human Services. Organ Procurement and Transplantation Network: Final Rule; 42 CFR-Part 121. Federal register, October 20, 1999; 56649.